A Randomization, Double-blind, Active-controlled, Multicenter, Phase 3 Trial to Evaluate the Efficacy and Safety of AD-224A and AD-224B in Patients With Essential Hypertension
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 254
- 试验地点
- 1
- 主要终点
- Change rate of MSSBP
研究概览
简要总结
The purpose of this study is to evaluate the efficacy and safety of AD-224
详细描述
Condition or disease : Essential Hypertension
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 19 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed informed consent
- •Patients with Essential Hypertension
- •Other inclusions applied
排除标准
- •Patient with Secondary Hypertension
- •Other exclusions applied
研究组 & 干预措施
AD-224C
Placebo of AD-224A+Placebo of AD-224B+AD-224C
干预措施: Placebo of AD-224A (Drug)
AD-224A
AD-224A+Placebo of AD-224B+Placebo of AD-224C
干预措施: Placebo of AD-224B (Drug)
AD-224B
Placebo of AD-224A+AD-224B+Placebo of AD-224C
干预措施: Placebo of AD-224A (Drug)
AD-224A
AD-224A+Placebo of AD-224B+Placebo of AD-224C
干预措施: Placebo of AD-224C (Drug)
AD-224B
Placebo of AD-224A+AD-224B+Placebo of AD-224C
干预措施: Placebo of AD-224C (Drug)
AD-224C
Placebo of AD-224A+Placebo of AD-224B+AD-224C
干预措施: AD-224C (Drug)
AD-224C
Placebo of AD-224A+Placebo of AD-224B+AD-224C
干预措施: Placebo of AD-224B (Drug)
AD-224A
AD-224A+Placebo of AD-224B+Placebo of AD-224C
干预措施: AD-224A (Drug)
AD-224B
Placebo of AD-224A+AD-224B+Placebo of AD-224C
干预措施: AD-224B (Drug)
结局指标
主要结局
Change rate of MSSBP
时间窗: Baseline, Week 8
Change from baseline in mean sitting systolic blood pressure
次要结局
未报告次要终点